Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition

Area of Science:

• Oncology
• Immunology
• Interventional Radiology

Background:

• Immunotherapy has revolutionized cancer treatment, yet many solid tumors remain unresponsive.
• Tumor evasion mechanisms limit durable responses to current immunotherapies.
• Stimulating immune responses in "cold" tumors is a critical research area.

Purpose of the Study:

• To review current clinical trials combining locoregional therapy and immune checkpoint inhibitors.
• To explore the potential of locoregional approaches in overcoming immunotherapy resistance.
• To identify future research directions for enhancing anti-tumor immunity.

Main Methods:

• Overview of ongoing clinical trials investigating combined locoregional therapy and immune checkpoint inhibitors.
• Analysis of strategies aimed at converting immunologically "cold" tumors to "hot" tumors.
• Literature review of preclinical and clinical data supporting this therapeutic combination.

Main Results:

• Several trials are actively evaluating the efficacy of combining locoregional therapies with immune checkpoint inhibitors.
• Locoregional therapies show promise in modulating the tumor microenvironment to enhance immunotherapy effectiveness.
• Preliminary data suggests potential for improved durable responses in select solid tumors.

Conclusions:

• Combining locoregional therapy with immune checkpoint inhibitors is a promising strategy to improve outcomes in solid organ tumors.
• Further research is needed to elucidate optimal combinations and patient selection criteria.
• Interventional radiology plays a key role in developing and testing these novel therapeutic approaches.